COC Taper Regimen for Acute Bleeding
For acute abnormal uterine bleeding, administer a monophasic combined oral contraceptive containing 35 mcg ethinyl estradiol three times daily for 7 days, then taper to once daily for 21 days. This represents the most evidence-based approach for hemodynamically stable patients requiring immediate medical intervention 1.
Treatment Algorithm
Initial Assessment
Before initiating therapy, confirm:
- Hemodynamic stability (if unstable, this requires different management)
- Negative pregnancy test
- No contraindications to estrogen (active VTE, stroke, migraine with aura, uncontrolled hypertension, known thrombophilia)
- Rule out structural causes if clinically indicated (polyps, fibroids, malignancy)
Dosing Regimen
Week 1 (Days 1-7):
- Monophasic COC (1 mg norethindrone/35 mcg ethinyl estradiol or equivalent) three times daily
- This high-dose phase rapidly stabilizes the endometrium
Weeks 2-4 (Days 8-28):
- Same COC once daily
- Completes the hormonal cycle and prevents recurrent bleeding
Expected Outcomes
- Median time to bleeding cessation: 3 days 1
- Emergency surgical intervention avoided in 95-100% of cases 1
- Bleeding stops in 76-88% of patients by day 14 1
Important Clinical Considerations
Common Pitfalls to Avoid
Single-dose regimens are inadequate: While some providers prescribe single-dose COCs for acute bleeding 2, the evidence supports multidose tapered regimens for superior efficacy 1. Emergency department physicians tend to use single-dose approaches more frequently than gynecologists, but this reflects lack of standardization rather than best practice 2.
Nausea management: The three-times-daily dosing causes nausea and bloating in many patients. Counsel patients to expect this and consider prophylactic antiemetics. Despite side effects, compliance is generally acceptable when patients understand the treatment rationale 1.
Contraceptive continuation: After completing the 28-day regimen, transition patients to standard cyclic or continuous COC use if ongoing contraception is desired, or provide alternative contraceptive counseling.
Alternative Considerations
When COCs Are Contraindicated
If estrogen-containing products cannot be used due to VTE risk or other contraindications:
- Medroxyprogesterone acetate 20 mg three times daily for 7 days, then 20 mg once daily for 21 days is equally effective 1
- Norethindrone acetate (progestin-only) is increasingly used by pediatric gynecologists, particularly in adolescents 2
- Tranexamic acid can be used in patients at high VTE risk without increasing thrombotic complications 3
For Ongoing Bleeding on Extended/Continuous CHC
The 2024 CDC guidelines address a different scenario—breakthrough bleeding in patients already using continuous CHCs 4. For these patients, a 3-4 day hormone-free interval may help, but this is not recommended during the first 21 days of use and not more than once monthly due to reduced contraceptive efficacy 4, 5.
Key Distinction
This question asks about acute bleeding treatment, not breakthrough bleeding management. The multidose taper regimen (three times daily × 7 days, then once daily × 21 days) is specifically for acute hemorrhagic episodes requiring immediate intervention 1. This differs from managing nuisance breakthrough bleeding in established contraceptive users, where NSAIDs or brief hormone-free intervals may suffice 4.
The evidence strongly supports the structured taper approach over ad-hoc single-dose regimens commonly used in emergency settings 2. This protocol provides rapid endometrial stabilization while minimizing the need for surgical intervention 1.